How Should Lipids and Medical Therapy be Managed in CLTI Patients and Those Undergoing Interventions for PAD

John R. Laird
Adventist Heart and Vascular Institute
St. Helena, CA

Acc/AHA Guideline-Recommended Therapies for PAD

- Class I
  - Aspirin
  - Statin medications
  - Smoking Cessation
- Class IIa
  - ACE inhibitors

Adherence to all 4 Guidelines Based Therapies

36% reduction in MACE
45% reduction in MALE

Disclosure Statement of Financial Interest

John R. Laird

- Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below.
- Affiliation/Financial Relationship
  - Consulting Fees/Honoraria
    - Boston Scientific, Medtronic, Abbott, BD Peripheral Intervention
  - Scientific Advisory board options
    - Reflow Medical, Endoluminal Sciences, Suturenver, PG Bypass, Evrin Medical, Shockwave Medical, Neovasc.

Based Member VIVA Physicians
What About Statins in PAD and CLI?

Lipid Lowering and Plaque Stabilization

VEITH 2018

Statin Use Associated with significant survival advantage at 1 year: 86% vs. 81%, p=0.03

VEITH 2018

From the Peripheral Vascular Society

Statin therapy is associated with superior clinical outcomes after endovascular treatment of critical limb ischemia

VEITH 2018

Effect of Statin Treatment on Limb Vascular Events

Decreased Hazard of MACE in Statin Group

VEITH 2018
**Summary of Recommendations**

- **If age < 75, Initiate high intensity statin (Atorvastatin 40 mg or 80 mg, Rosuvastatin 20 mg or 40 mg)**
- **If LDL-C > 70 mg/dl on maximally tolerated statin therapy, it is reasonable to add ezetimibe therapy (IIa)**
- **If LDL-C > 70 mg/dl on maximally tolerated LDL-C lowering therapy, it is reasonable to add PCSK9 inhibitor (following a discussion about net benefit, safety, and cost)(IIa)**

**Efficacy of Evolocumab**

- 3,642 patients with PAD
- Evolocumab reduced primary endpoint in patients with PAD
- Evolocumab reduced major adverse limb events
- Reduction in median LDL level from 94 mg/dl to 31 mg/dl
<table>
<thead>
<tr>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Appropriate medical care in patients with lower extremity disease is critically important to reduce the risk of major adverse cardiovascular events</td>
</tr>
<tr>
<td>• Adherence to guidelines based therapy does make a difference!</td>
</tr>
<tr>
<td>• Aggressive lipid lowering therapy is a cornerstone of therapy – strive to achieve the lowest LDL possible!</td>
</tr>
</tbody>
</table>

Thank You!